Evogene Ltd. (EVGN) is a Materials stock. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Understand Evogene Ltd.: how it makes money
Evogene is a chemicals and materials company that earns revenue by producing and selling chemical products. At its current scale, quarterly revenue is negligible while the operating cost base runs several times larger, keeping the business firmly in the red.
Unit-level chemistry economics are workable (roughly 49% of each sale kept as gross profit), but the fixed operating load is calibrated for a revenue base the company has not yet reached.
Business quality (Unprofitable): Unprofitable with operating losses nearly three times revenue; the cost structure is not yet matched to the top line.
Bull case
Gross margin shows viable chemistry: A 49% gross margin indicates that when product reaches the market, the underlying unit economics are sound for a chemicals producer, leaving room to absorb operating costs as volume grows.
Bear case
Costs run 3x revenue: The operating margin sits at -189%, meaning the company spends roughly three dollars for every one it earns. Until revenue scales substantially, the quarterly loss will continue to drain the balance sheet.
Revenue is shrinking fast: Top-line revenue fell 37% year over year in the latest quarter, signaling that demand, pricing, or customer uptake is contracting at a critical early-growth stage rather than expanding.
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)
$3.85M
Net Margin
-203.1%
Return on Equity
-65.4%
Current Ratio
4.54
Revenue Growth (YoY)
-54.7%
EPS Growth (YoY)
-137.4%
Valuation vs Sector & Industry
Sector P/E (Materials)
23.9
Industry P/E (Chemicals)
32.1
Company
Sector
Materials
Industry
Chemicals
Related Companies (Chemicals; 8 comparable chemical companies)